HLA expression in choroidal melanomas: Correlation with clinicopathological features

Current Eye Research

Volumn 28, Issue 6, 2004, Pages 409-416

  Krishnakumar, Subramanian ^a,b   Abhyankar, Dhiraj ^c   Lakshmi, Sundaram Amirtha ^a   Pushparaj, Vaijayanthi ^a   Shanmugam, Mahesh Palanivelu ^b   Biswas, Jyotirmay ^a  

^a Sankara Nethralaya ^*  (India)

^b VISION RESEARCH FOUNDATION   (India)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Beta 2 microglobulin; HLA; Immunohistochemistry; Melanoma; Metastases

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; HLA ANTIGEN; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PEROXIDASE; TUMOR MARKER;

ADULT; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CELL TYPE; CHOROID MELANOMA; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; EPITHELIOID CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOREACTIVITY; LIVER METASTASIS; MALE; MEDICAL PARAMETERS; MICROSCOPY; MITOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SPINDLE CELL; STATISTICAL SIGNIFICANCE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; UVEA MELANOMA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BETA 2-MICROGLOBULIN; CHOROID NEOPLASMS; EYE NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SCLERAL DISEASES;

EID: 4143062824     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680490503741     Document Type: Article

References (20)

1. Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: A review. Surv Ophthalmol. 1996;41:215-228.
2. Österlind A. Trends in incidence of ocular malignant melanoma in Denmark 1943-1982. Int J Cancer. 1987;40:161-164.
3. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334-336.
4. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997;18:267-268.
5. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabell F, Stern PL. Natural history of HLA expression during tumor development. Immunol Today. 1993;14:491-499.
6. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defense strategy. Nature. 1986;319:675-678.
7. Ma D, Niederkorn JY. Transforming growth factor-β down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology. 1995;86:263-269.
8. Biswas J, Krishnakumar S, Shanmugam MP. Uveal melanoma in Asian Indians: A clinicopathological study. Arch Ophthalmol. 2002;120:522-523.
9. Folberg R, Gamel JW, Greenberg RA, Donoso LA, Naids RM. Comparison of direct and micro slide pathology measurements of uveal melanomas. Invest Ophthalmol Vis Sci. 1985;26:1788-1791.
10. Callender GR. Malignant melanotic tumors of the eye: A study of histologic type in 111 cases. Trans Am Acad Ophthalmol Otolaryngol. 1931;36:131-142.
11. Eder DE, Murphy GF. Atlas of Tumor Pathology. Melanocytic Tumors of the Skin. Washington: Armed Forces Institute of Pathology; 1991:159.
12. Biswas J, Raghavendran R, Ratra V, Krishnakumar S, Gopal L, Shanmugam MP. Diffuse malignant melanoma of the choroid simulating metastatic tumor to the choroid. Ind J Ophthalmol. 2000;48:137-140.
13. Pende D, Accame L, Pareti L, Mazzocchi A, Moretta A, Parmiani G, Moretta L. The susceptibility to natural killer cell-mediated lysis of HLA class 1-positive melanoma reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol. 1998;28:2384-2394.
14. Blom DJ, Luyten GPM, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I expression, marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997;38:1865-1872.
15. Blom DJ, Schurmans LR, De Waard-Siebinga I, De Wolff-Rouendaal D, Keunen JE, Jager MJ. HLA expression in a primary uveal melanoma, its cell line, and four of its metastases. Br J Ophthalmol. 1997;81:989-993.
16. Crowder J, Dithmar S, Jager MJ, Hurks HMH, Vigneswaran N, Grossniklaus HE. HLA class I antigen expression correlates with epithelioid cell type in uveal melanoma. Invest Ophthalmol Vis Sci. 2000;41:S384.
17. Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O. Association of HLA class I and Class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42:2153-2156.
18. Dithmar S, Crowder J, Jager MJ, Vigniswaran N, Grossniklaus HE. HLA class I antigen expression correlates with histological cell type in uveal melanoma. Ophthalmologe. 2002;99;625-628.
19. Ljunggren HG, Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today. 1990;11:237-244.
20. Xie J, Wang Y, Freeman ME, Barlogie B, Yi Q. (Beta) 2-microglobulin as a negative regulator of the immune system: High concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood. 2003:1-21.